Elevated METTL3 expression and an increased global m6A percentage of FSHD myoblasts highlight a dysregulated RNA modification landscape, which contributes to the molecular complexity of the disease. This evidence concerns the gene METTL3 and facioscapulohumeral muscular dystrophy.